a year ago
SANA
AnalystsEmily BodnarEmily Bodnar's Stock Forecasts
AnalystsEmily Bodnar
Sectors:
Analyst Ranking
Bottom 4%
#5041 out of 5228 analysts
Average Return
-2.83%
Win Rate
28%92 out of 329
Risk vs Reward
Poor
Good
Emily Bodnar's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Rapt Therapeutics IncRAPT | +738.60% | $6.87 | $57.57 | 2025-05-21 - 2026-01-20 | Buy |
Rapt Therapeutics IncRAPT | +567.87% | $8.62 | $57.57 | 2025-07-09 - 2026-01-20 | Buy |
Connect Biopharma Holdings LtdCNTB | +510.91% | $0.55 | $3.36 | 2025-03-30 - 2026-03-25 | Buy |
Connect Biopharma Holdings LtdCNTB | +487.41% | $0.57 | $3.36 | 2025-03-31 - 2026-03-25 | Buy |
Olema Pharmaceuticals IncOLMA | +471.36% | $4.26 | $24.34 | 2025-03-04 - 2026-03-04 | Buy |
Emily Bodnar Analyst Color
Get additional color on Emily Bodnar's coverage of popular stocks
2 years ago
FEMY
Emily Bodnar's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Purple Biotech LtdPPBT | 14 | Buy | $30.00 | +624.64% | Maintains | 13 days ago |
Sab Biotherapeutics IncSABS | 3 | Buy | $7.00 | +83.25% | Maintains | 16 days ago |
Sana Biotechnology IncSANA | 12 | Buy | $7.00 | +125.81% | Maintains | 22 days ago |
Anaptysbio IncANAB | 13 | Buy | $66.00 | +0.93% | Maintains | 22 days ago |
Arcus Biosciences IncRCUS | 8 | Buy | $32.00 | +49.11% | Reiterates | 24 days ago |
Novocure LtdNVCR | 22 | Buy | $49.00 | +322.05% | Maintains | a month ago |
Arcellx IncACLX | 15 | Hold | $115.00 | +0.40% | Downgrades | a month ago |
Autolus Therapeutics PLCAUTL | 1 | Buy | $9.00 | +576.69% | Initiates Coverage On | a month ago |
Agios Pharmaceuticals IncAGIO | 5 | Buy | $65.00 | +119.67% | Maintains | a month ago |
Rapt Therapeutics IncRAPT | 4 | Hold | $58.00 | -0.03% | Downgrades | 2 months ago |
Ventyx Biosciences IncVTYX | 15 | Hold | $14.00 | 0.00% | Downgrades | 3 months ago |
Vtv Therapeutics IncVTVT | 3 | Buy | $47.00 | +22.72% | Maintains | 3 months ago |
Olema Pharmaceuticals IncOLMA | 22 | Buy | $45.00 | +217.57% | Maintains | 4 months ago |
Acrivon Therapeutics IncACRV | 12 | Buy | $19.00 | +1,150.00% | Reiterates | 4 months ago |
Artiva Biotherapeutics IncARTV | 2 | Buy | $15.00 | +174.73% | Maintains | 4 months ago |
Context Therapeutics IncCNTX | 11 | Buy | $5.00 | +87.27% | Maintains | 5 months ago |
Senti Biosciences IncSNTI | 1 | Buy | $12.00 | +1,262.09% | Initiates Coverage On | 5 months ago |
Tg Therapeutics IncTGTX | 1 | Buy | $60.00 | +88.56% | Assumes | 6 months ago |
Agenus IncAGEN | 14 | Buy | $23.00 | +546.07% | Reiterates | 7 months ago |
Briacell Therapeutics CorpBCTX | 15 | Buy | $40.00 | +887.65% | Maintains | 7 months ago |
Mink Therapeutics IncINKT | 14 | Buy | $35.00 | +283.56% | Upgrades | 7 months ago |
Femasys IncFEMY | 25 | Buy | $8.00 | +1,459.45% | Maintains | 7 months ago |
Jasper Therapeutics IncJSPR | 10 | Buy | $20.00 | +1,734.86% | Maintains | 9 months ago |
Nextcure IncNXTC | 9 | Buy | $36.00 | +253.29% | Reiterates | 9 months ago |
Transcode Therapeutics IncRNAZ | 17 | Buy | $280.00 | +3,178.69% | Maintains | a year ago |
Connect Biopharma Holdings LtdCNTB | 6 | Buy | $8.00 | +138.10% | Reiterates | a year ago |
Io Biotech IncIOBT | 13 | Buy | $12.00 | +6,117.62% | Reiterates | a year ago |
Genelux CorpGNLX | 7 | Buy | $30.00 | +1,032.08% | Reiterates | a year ago |
Nkarta IncNKTX | 13 | Buy | $18.00 | +745.07% | Reiterates | a year ago |
Imunon IncIMNN | 13 | Buy | $210.00 | N/A | Reiterates | a year ago |
Atossa Therapeutics IncATOS | 13 | Buy | $35.00 | N/A | Reiterates | a year ago |
Acelyrin IncSLRN | 13 | Hold | $6.00 | N/A | Maintains | a year ago |
Geron CorpGERN | 3 | Buy | $9.00 | N/A | Reiterates | a year ago |
Gracell Biotechnologies IncGRCL | 6 | Hold | $10.00 | N/A | Downgrades | 2 years ago |
Dice Therapeutics IncDICE | 8 | Hold | $48.00 | N/A | Reiterates | 3 years ago |
Sqz Biotechnologies CoSQZB | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.